AAV Compositions for F8 Gene Correction Without Exogenous Nucleases
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current gene therapy methods for treating hemophilia A, such as those using retroviral vectors and nuclease-based technologies, pose safety concerns due to potential off-target mutations and genomic disruptions, necessitating the development of safer and more efficient approaches to restore F8 gene function.
Innovation Solution
Adeno-associated virus (AAV) compositions are developed, which include a replication-defective AAV capsid and a correction genome with homology arms for editing the F8 gene, allowing for efficient correction of mutations without the need for exogenous nucleases, thereby minimizing safety risks and improving therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If retroviral vectors are used for gene therapy, then F8 gene function can be restored, but safety concerns arise due to potential off-target mutations and genomic disruptions
Solution Approach 1:
The patent uses adeno-associated virus (AAV) as an intermediary vector system to deliver nuclease components and homology arms to target cells. AAV serves as a safe delivery vehicle that does not integrate into the host genome like retroviral vectors, thereby avoiding off-target mutations while still enabling precise F8 gene correction through homologous recombination
Solution Approach 2:
The gene therapy system is segmented into separate functional components: (1) AAV-delivered nuclease component for creating targeted double-strand breaks, (2) AAV-delivered homology arms containing the correct F8 gene sequence, and (3) cellular machinery for homologous recombination. This segmentation allows each component to perform its specific function independently, improving safety and precision
2Manufacturing precision
If nuclease-based gene editing technologies are used, then F8 gene defects can be corrected, but safety concerns arise due to potential off-target mutations
Solution Approach 1:
The patent employs homology arms with sequences that are highly specific to the target F8 gene locus. These homology arms ensure that the nuclease-induced double-strand break is repaired only at the intended location through homologous recombination, thereby achieving local precision in gene correction while avoiding off-target mutations at other genomic sites
Solution Approach 2:
The system incorporates feedback mechanisms where the nuclease component is designed to recognize and bind specifically to the mutant F8 gene sequence, creating double-strand breaks only at the target locus. The subsequent homologous recombination process is guided by the homology arms, which provide feedback to ensure accurate repair at the correct location, thereby preventing off-target effects
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The AAV compositions effectively correct F8 gene mutations in vivo, reducing the risk of off-target effects and enhancing the safety and efficiency of gene therapy for hemophilia A treatment, providing a promising cure for the disorder.
Implementation Method 1
Adeno-associated virus (AAV) compositions are developed, which include a replication-defective AAV capsid and a correction genome with homology arms for editing the F8 gene
Data Source
AI summary
Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease. Also provided are methods of using the AAV compositions to correct an F8 gene mutation and/or treat a disease or disorder associated with an F8 gene mutation. Packaging systems for making the adeno-associated virus compositions are also provided.